New hope for kids with rare kidney disease
NCT ID NCT05001269
Summary
This study tested a drug called nedosiran in children from birth to 11 years old who have primary hyperoxaluria, a rare genetic disease that causes kidney stones and can lead to kidney failure. The main goal was to see if the monthly treatment safely lowers the harmful oxalate levels in the children's urine and helps protect their kidney function. Researchers also closely monitored the drug's safety and how it works in the body of these young patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPEROXALURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Rochester, Minnesota, 55905, United States
-
Clinical Research Site
Hamilton, Ontario, L8S 4K1, Canada
-
Clinical Research Site
Heidelberg, 69120, Germany
-
Clinical Research Site
Fukuoka, 830-0011, Japan
-
Clinical Research Site
Nagoya, 467-8602, Japan
-
Clinical Research Site
Beirut, 1100, Lebanon
-
Clinical Research Site
Bialystok, 15-274, Poland
-
Clinical Research Site
Barcelona, 08035, Spain
-
Clinical Research Site
Yenimahalle, Ankara, 06506, Turkey (Türkiye)
-
Clinical Trial Site
Bonn, 53127, Germany
-
Clinical Trial Site
Roma, 00165, Italy
-
Clinical Trial Site
Dubai, +971, United Arab Emirates
-
Clinical Trial Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.